Stereotactic ablative radiotherapy (SABR) can increase the immunogenicity of tumours through modulation of the tumour and its environment. Several, mostly small, non-randomised trials have investigated combining SABR with immune checkpoint inhibitors (ICI) to increase their therapeutic potential. This study provides a comprehensive view of all prospective clinical trials and pooled analyses of important clinical outcomes. The combination seemed safe with promising outcomes.
Christopher Weil
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Christopher
Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack